In today’s briefing:
- Bio-Techne Corp: Advanced Cell Diagnostics RNAscope System Developments & Other Drivers
- Boston Scientific: The Lux-Dx ICM Launch & Other Drivers
- China Resources Pharmaceutical (3320.HK) – Here Are the Concerns
- Stryker Corporation: The Monterey AL Launch & Other Drivers
Bio-Techne Corp: Advanced Cell Diagnostics RNAscope System Developments & Other Drivers
- Bio-Techne has been going through a tough 2022 and witnessed a slow summer especially in the European markets as well as Covid-related shutdowns in China.
- The company did manage to achieve some organic revenue growth but failed to meet Wall Street expectations in terms of revenues as well as earnings.
- The company recently announced the release of the automated codetection assays for the company’s Advanced Cell Diagnostics RNAscope system for in-situ hybridization.
Boston Scientific: The Lux-Dx ICM Launch & Other Drivers
- Boston Scientific reported a mixed set of results as it surpassed Wall Street expectations on the revenue front but delivered an earnings miss in light of the ongoing supply chain and macroeconomic headwinds.
- Overall, company operational sales grew, and organic sales also grew.
- Six of the eight business units of the company have grown organically in the double-digits.
China Resources Pharmaceutical (3320.HK) – Here Are the Concerns
- The distribution business is stable, but it’s difficult to achieve high growth/profits due to industry trend. Therefore, the valuation of this business is hard to increase.
- The performance of pharmaceutical manufacturing business is important, which largely determines the overall profit margin. But it actually depends on what the subsidiaries can contribute, who are facing different challenges.
- China Resources Pharmaceutical may need to improve its vision of asset selection and its ability to judge and grasp the long-term trend of the industry. The current valuation isn’t attractive.
Stryker Corporation: The Monterey AL Launch & Other Drivers
- Stryker delivered a mixed set of results for the quarter and managed to surpass Wall Street expectations on the revenue front.
- The demand for the company’s capital products stayed quite strong in this quarter, as viewed by the growth of double-digit of its medical division.
- Also, the Instruments business experienced challenges in the supply chain mainly related to the company’s capital products.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
